Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAXIPEM: axitinib ± pembrolizumab in first-line papillary renal cell carcinoma
2021-001065-21Phase 2Active
- Sponsor
- Centre Léon Bérard
- Start
- Apr 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in renal cell carcinoma (RCC) and metastatic renal cell carcinoma (mRCC) comparing Axitinib monotherapy with Axitinib + pembrolizumab (2 arms). Primary endpoint: objective response rate. Started Apr 2021; status: active.
02
Drugs
axitinibpembrolizumab
03
Conditions
renal cell carcinoma (RCC)metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on 2021-001065-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001065-21.